NCT03773666 is a Phase 1 clinical trial of Durvalumab in Muscle Invasive Bladder Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT03773666?

NCT03773666 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT03773666?

Interventions in NCT03773666: Durvalumab, Oleclumab.

What condition does NCT03773666 study?

NCT03773666 studies Muscle Invasive Bladder Cancer.

Is NCT03773666 still recruiting?

NCT03773666 is currently completed. Last updated 13 September 2022.

Last reviewed 2022-09-13 · How we verify

NCT03773666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Completed Phase 1 Last updated 13 September 2022

What this trial tests

Phase 1 trial testing Durvalumab in Muscle Invasive Bladder Cancer in 12 participants. Completed in 2 August 2021.

Timeline

20 February 2019

Primary endpoint
4 February 2021

2 August 2021

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	20 February 2019
Primary completion	4 February 2021
Estimated completion	2 August 2021
Sites	2 locations across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Oleclumab — full drug profile →

Conditions studied

Muscle Invasive Bladder Cancer — all drugs for Muscle Invasive Bladder Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Muscle Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer. The drugs involved in this study are: * Durvalumab (MEDI4736) * Oleclumab (MEDI9447)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, et al · · 2019 · cited 326× · PMID 31244820 · DOI 10.3389/fimmu.2019.00925
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
ATP and cancer immunosurveillance.
Kepp O, Bezu L, Yamazaki T, Di Virgilio F, et al · · 2021 · cited 171× · PMID 34121201 · DOI 10.15252/embj.2021108130
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Giannone G, Ghisoni E, Genta S, Scotto G, et al · · 2020 · cited 119× · PMID 32575899 · DOI 10.3390/ijms21124414
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy.
Hao Z, Li R, Wang Y, Li S, et al · · 2021 · cited 72× · PMID 34689842 · DOI 10.1186/s40364-021-00333-5
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB, Phan LH, Villarreal OE, Bowser JL. · · 2020 · cited 72× · PMID 32351498 · DOI 10.3389/fimmu.2020.00508
Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA, Powell JD. · · 2021 · cited 61× · PMID 32903139 · DOI 10.1146/annurev-med-060619-023155
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X, Xie L. · · 2022 · cited 54× · PMID 35836249 · DOI 10.1186/s13046-022-02430-1

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Muscle Invasive Bladder Cancer

Currently open trials in the same condition.

NCT07202819 — Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy · NA · recruiting
NCT06916494 — Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-r · Phase 1 · recruiting
NCT04960709 — Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patient · Phase 3 · active not recruiting
NCT03732677 — Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC · Phase 3 · active not recruiting
NCT02546661 — Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03773666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 13 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03773666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing